Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for co…
This bill permanently places 2-benzylbenzimidazole opioids (commonly called nitazenes) into Schedule I of the Controlled Substances Act by adding a broad structural-and-activity definition and listing several named compounds.
Substances temporarily scheduled under existing emergency authority are deemed permanently Schedule I on enactment.
The Attorney General must issue implementing rules within one year, may use an interim final rule effective immediately without demonstrating good cause, may publish a list of covered substances, and must allow comment and hearings before issuing a final rule.
Content is narrow and safety‑oriented which helps prospects, but classwide scheduling controversy, potential legal challenges, and absence of research carveouts lower odds.
Relative to its intended legislative type, this bill is a straightforward substantive amendment to the Controlled Substances Act that is legally specific and well-integrated with existing statutory provisions and administrative procedure. It provides a clear mechanism and timeline for implementation.
Progressives emphasize research and harm-reduction risks
Progressives emphasize research and harm-reduction risks
Generally supportive of stronger tools to remove highly potent synthetic opioids from illicit markets because of overdose harms.
Concerned that Schedule I classification constrains research, harm-reduction efforts, and could intensify criminal penalties for people who use drugs.
Would want guarantees of research exemptions, funding for treatment, and measures to avoid prosecuting low-level users.
Pragmatic support for closing a legal loophole that novel nitazenes exploit, while weighing administrative and legal tradeoffs.
Wants clear, narrowly tailored definitions and procedural safeguards to limit unintended consequences and litigation risk.
Sees value in swift action but prefers accompanying oversight and coordination with health agencies.
Strongly supportive of permanent, enforceable restrictions on highly dangerous synthetic opioids to protect public safety and communities.
Views the bill as a necessary law-enforcement tool against lethal designer drugs.
Some conservatives may still worry about administrative overreach, but many will accept expedited rulemaking given urgency.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow and safety‑oriented which helps prospects, but classwide scheduling controversy, potential legal challenges, and absence of research carveouts lower odds.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize research and harm-reduction risks
Content is narrow and safety‑oriented which helps prospects, but classwide scheduling controversy, potential legal challenges, and absence…
Relative to its intended legislative type, this bill is a straightforward substantive amendment to the Controlled Substances Act that is legally specific and well-integrated with existing statutory provisions and admini…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.